Dr. Zbigniew Zasłona currently serves as Chief Scientific Officer at Molecure. He also manages the Department of Biology. He obtained his PhD in 2010 at the University of Giessen and the Marburg Lung Center in Germany, studying the mechanisms
Read more- Significant partnership agreement with the world-renowned International Institute of Molecular and Cell Biology in Warsaw (IIMCB) to accelerate the strategic development of OncoArendi’s small molecule RNA platform - Novel dual acting first-in-class arginase inhibitor OATD-02
Read more- Significant partnership agreement with the world-renowned International Institute of Molecular and Cell Biology in Warsaw (IIMCB) to accelerate the strategic development of OncoArendi’s small molecule RNA platform - Novel dual acting first-in-class arginase inhibitor OATD-02
Read more- Option to in-license and develop small molecule leads against a novel target for the treatment of fibrotic diseases - Strengthens pipeline and reinforces OncoArendi’s strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF) 11
Read moreNew members to bring additional scientific, operational and HR expertise Warsaw, Poland – 31 January 2022 - OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to
Read moreNew members to bring additional scientific, operational and HR expertise Warsaw, Poland – 31 January 2022 - OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to
Read moreDr. Fung to Lead Global Clinical Development, Translational Science and Regulatory Strategies Warsaw, Poland – 27 January 2022 - OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal
Read moreDr. Fung to Lead Global Clinical Development, Translational Science and Regulatory Strategies Warsaw, Poland – 27 January 2022 - OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal
Read moreOncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members Appointments bring global leadership experience and expertise in drug discovery, as well as clinical
Read more
